Brexanolone (Zulresso): A Comprehensive Monograph on the First-in-Class Neurosteroid for Postpartum Depression

Executive Summary

Brexanolone, marketed under the brand name Zulresso, represents a landmark development in psychiatric pharmacotherapy as the first medication specifically approved by the U.S. Food and Drug Administration (FDA) for the treatment of postpartum depression (PPD).[1] A synthetic, injectable formulation of the endogenous neurosteroid allopregnanolone, Brexanolone introduced a novel therapeutic mechanism for a major depressive disorder subtype. Its primary mechanism of action is the positive allosteric modulation of gamma-aminobutyric acid type A (

GABAA​) receptors, which enhances central nervous system inhibition and is hypothesized to counteract a neurosteroid deficiency state believed to underlie PPD in susceptible individuals.[3]

Clinical trials demonstrated a rapid and robust antidepressant effect, with statistically and clinically significant reductions in depressive symptoms, as measured by the Hamilton Rating Scale for Depression (HAM-D), observed within 60 hours of initiating treatment.[2] This rapid onset of action offered a profound advantage over traditional antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), which typically require several weeks to elicit a therapeutic response.

However, the clinical utility of Brexanolone was significantly constrained by its safety profile and administration requirements. The primary safety concern was a risk of excessive sedation and sudden loss of consciousness, which prompted the FDA to issue a Boxed Warning and mandate a highly restrictive Risk Evaluation and Mitigation Strategy (REMS) program.[6] The REMS program required administration via a continuous 60-hour intravenous infusion in a certified healthcare facility under constant medical supervision, creating substantial logistical, emotional, and financial barriers for patients and healthcare systems.[9]

These practical challenges, combined with a high acquisition cost, severely limited its market adoption. The subsequent development and approval of Zuranolone, an oral neurosteroid with a similar mechanism but a more convenient 14-day oral dosing regimen, rendered the burdensome intravenous formulation strategically obsolete. Consequently, Sage Therapeutics, the developer of both agents, announced the discontinuation of Zulresso, with the formal withdrawal of its New Drug Application effective in 2025.[12] Despite its short commercial lifespan, Brexanolone's legacy is significant; it successfully validated the neurosteroid pathway as a legitimate therapeutic target for mood disorders and catalyzed the development of a new generation of more accessible treatments for PPD.

Introduction: A Paradigm Shift in Postpartum Depression Treatment

The Unmet Need in Postpartum Depression

Postpartum depression (PPD) is one of the most common medical complications of childbirth, a serious and potentially life-threatening mood disorder affecting an estimated 10% to 20% of women worldwide.[2] Far more severe than the transient "baby blues," PPD is a major depressive episode characterized by symptoms such as profound sadness, anhedonia, anxiety, fatigue, feelings of worthlessness, and, in severe cases, suicidal ideation.[15] The condition can have devastating consequences, impairing a mother's ability to function and care for herself and her infant. It can profoundly disrupt the critical maternal-infant bond, which is foundational for healthy child development, and is associated with adverse cognitive and emotional outcomes in children.[1] The societal and personal burden of PPD underscores a long-standing and critical unmet medical need for effective and timely interventions.

Limitations of Existing Therapies

For decades, the standard of care for PPD relied on treatments developed for major depressive disorder (MDD) in the general population, primarily psychotherapy and pharmacotherapy with agents like selective serotonin reuptake inhibitors (SSRIs).[9] While these therapies can be effective for some women, they possess significant limitations in the acute postpartum context. The most notable drawback of SSRIs and other traditional antidepressants is their delayed onset of action, typically requiring two to six weeks, and sometimes longer, to achieve a meaningful clinical response.[3] This therapeutic lag represents a period of continued suffering and risk for both the mother and child. Furthermore, the efficacy of these agents in PPD has not been as robustly studied as in MDD, and a substantial portion of women do not achieve adequate symptom relief.[15] This gap in care highlighted the urgent need for a treatment specifically designed for the unique pathophysiology of PPD that could offer rapid symptom relief.

Brexanolone as a Breakthrough Therapy

The development of Brexanolone marked a pivotal moment in the management of PPD. In March 2019, it became the first and only medication to be specifically approved by the U.S. FDA for this indication, representing a paradigm shift in the field.[1] In recognition of its potential to offer a substantial improvement over existing therapies, the FDA had previously granted Brexanolone a Breakthrough Therapy Designation.[2]

This designation was not merely based on its novel indication but on its fundamentally different therapeutic approach. Rather than repurposing a general antidepressant targeting monoaminergic systems, the development of Brexanolone was driven by a specific hypothesis regarding the neurobiology of PPD. Research had increasingly pointed to the dramatic hormonal fluctuations of the peripartum period, particularly the precipitous drop in progesterone and its primary neuroactive metabolite, allopregnanolone, immediately following childbirth.[2] This sudden neurosteroid withdrawal was theorized to cause a dysregulation of the brain's primary inhibitory system, mediated by the

GABAA​ receptor, leading to the mood and anxiety symptoms characteristic of PPD.[3] Brexanolone was designed as a direct intervention to address this hypothesized deficiency, acting as a synthetic replacement for allopregnanolone to restore inhibitory tone in the CNS.[1] Its approval thus served as a clinical validation of this neurosteroid hypothesis, heralding a move away from broad, symptom-based treatment and toward a more precise, pathophysiology-driven strategy in psychiatric medicine.

Physicochemical Properties and Molecular Identification

Chemical Identity

Brexanolone is a small molecule drug classified as a pregnane neurosteroid.[1] Its systematic chemical name is (3α,5α)-3-hydroxy-pregnan-20-one, and it is chemically identical to the endogenous neurosteroid allopregnanolone.[23] Allopregnanolone is a naturally occurring metabolite of the sex hormone progesterone, synthesized within the body.[1] As a pharmaceutical agent, this compound is referred to as Brexanolone.

Molecular and Physical Characteristics

The molecular formula for Brexanolone is C21​H34​O2​, and its relative molecular mass is 318.5 Da.[8] In its pure form, it is a white, crystalline solid with a melting point in the range of 176-178 °C.[23] A critical physicochemical property is its poor aqueous solubility, which presents a significant challenge for formulation and administration.[2] This inherent insolubility in water necessitates the use of a specialized intravenous formulation containing a solubilizing agent (betadex sulfobutyl ether sodium) to achieve therapeutic concentrations in the body, and it is the primary reason for its extremely low oral bioavailability of less than 5%.[8]

Identifiers and Classification

Brexanolone is registered and tracked across numerous chemical, pharmacological, and regulatory databases under a variety of unique identifiers. These are essential for accurate identification and cross-referencing in research and clinical practice. In the United States, Brexanolone is classified by the Drug Enforcement Administration (DEA) as a Schedule IV controlled substance under the depressant class, with the assigned DEA Code Number 2400.[1] This scheduling indicates a low potential for abuse and low risk of dependence relative to substances in Schedule III.[1] A comprehensive list of its key identifiers and properties is provided in Table 1.

Table 1: Brexanolone Identifiers and Physicochemical Properties

Identifier Type	Value	Source(s)
DrugBank ID	DB11859	1
CAS Number	516-54-1	1
Common Name	Brexanolone, Allopregnanolone	1
Brand Name	Zulresso	1
Chemical Name	(3α,5α)-3-hydroxy-pregnan-20-one	24
Molecular Formula	C21​H34​O2​	8
Molecular Weight	318.5 Da	8
Physical Form	White solid	23
Melting Point	176-178 °C	23
DEA Schedule	Schedule IV	1
DEA Code Number	2400	1
UNII	S39XZ5QV8Y	1

Pharmacology and Mechanism of Action

Primary Mechanism: GABA-A Receptor Modulation

The primary pharmacological action of Brexanolone is its function as a positive allosteric modulator of the gamma-aminobutyric acid type A (GABAA​) receptor.[9] GABA is the principal inhibitory neurotransmitter in the mammalian central nervous system, and its signaling is crucial for regulating neuronal excitability.[4] When GABA binds to a

GABAA​ receptor, it opens an intrinsic chloride ion channel, allowing chloride ions to flow into the neuron. This influx of negative charge hyperpolarizes the cell membrane, making the neuron less likely to fire an action potential and thus producing an inhibitory effect.[4]

As a positive allosteric modulator, Brexanolone does not activate the GABAA​ receptor on its own. Instead, it binds to a distinct site on the receptor complex and enhances the effect of GABA when it binds.[4] This potentiation of GABAergic inhibition is believed to be the core mechanism underlying its antidepressant, anxiolytic, and sedative effects.[1]

Interaction with Receptor Subunits

The GABAA​ receptors are a diverse family of ligand-gated ion channels, typically composed of five protein subunits arranged around a central pore. The specific combination of subunits determines the receptor's pharmacological properties and location within the brain. Brexanolone has been shown to potentiate GABA-mediated currents across a range of recombinant human GABAA​ receptor subtypes, including those containing α1β2γ2, α4β3δ, and α6β3δ subunits.[1] Its particularly potent effect on isoforms containing the δ (delta) subunit is noteworthy.[23]

This broad activity is central to its powerful effects. GABAA​ receptors can be broadly categorized by their location. Synaptic receptors, often containing γ subunits, are located directly at the synapse and mediate rapid, transient phasic inhibition in response to high concentrations of GABA released during neurotransmission. In contrast, extrasynaptic receptors, which frequently contain δ subunits, are located outside the synapse and are highly sensitive to low, ambient concentrations of GABA. These receptors mediate a persistent, steady form of inhibition known as tonic inhibition, which sets the overall excitability threshold for entire neural networks.[2] Dysregulation of this tonic inhibitory tone has been increasingly implicated in the pathophysiology of mood and anxiety disorders. Brexanolone's ability to positively modulate both synaptic and extrasynaptic

GABAA​ receptors allows it to enhance both phasic and tonic inhibition, providing a powerful and comprehensive dampening of the neuronal hyperexcitability or network dysregulation hypothesized to drive PPD symptoms. This dual action may explain its rapid and profound clinical effects, distinguishing it from other GABAergic agents that may act more selectively on synaptic receptors.

Distinction from Benzodiazepines

Although both Brexanolone and benzodiazepines enhance GABAA​ receptor function and share sedative properties, they do so through different mechanisms and binding sites. Benzodiazepines bind at the interface between α and γ subunits, increasing the frequency of channel opening in the presence of GABA. Brexanolone, as a neurosteroid, is believed to bind to a distinct transmembrane site on the receptor complex.[4] This mechanistic difference contributes to a distinct pharmacological profile and may explain why neurosteroids can modulate extrasynaptic receptors that are typically insensitive to benzodiazepines.

Role as a Neuroactive Steroid

Brexanolone is an exogenous formulation of allopregnanolone, a potent endogenous neuroactive steroid.[2] Its therapeutic rationale is deeply rooted in the "neurosteroid deficiency" hypothesis of PPD. During a normal pregnancy, levels of progesterone and, consequently, its metabolite allopregnanolone, increase steadily, reaching peak concentrations in the third trimester.[2] This sustained elevation of a potent positive allosteric modulator of

GABAA​ receptors is thought to be a key neuroprotective and mood-stabilizing adaptation to pregnancy.

However, following childbirth, the placenta is delivered, and plasma concentrations of progesterone and allopregnanolone plummet dramatically within hours.[3] It is hypothesized that in women who are susceptible to PPD, the brain's

GABAA​ receptors, having adapted to the high-neurosteroid environment of pregnancy, fail to readjust to this sudden withdrawal. This maladaptation leads to a state of GABAergic hypofunction and disinhibition, manifesting as anxiety, irritability, and depression.[2] Brexanolone therapy is designed to directly counteract this proposed pathophysiological cascade. By administering a continuous infusion of exogenous allopregnanolone, the treatment aims to temporarily restore the neurosteroid tone, stabilizing the dysregulated GABAergic system and allowing the receptors time to gradually re-adapt to the postpartum hormonal environment, effectively "resetting" the aberrant neural circuits.[4]

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of Brexanolone is characterized by its exclusive intravenous administration, extensive tissue distribution, non-CYP450 metabolism, and relatively rapid elimination. These properties are fundamental to its dosing regimen and clinical considerations.

Administration and Bioavailability

Brexanolone is administered solely as a continuous intravenous (IV) infusion over a 60-hour period.[8] This route is necessary due to its extremely poor oral bioavailability, which is less than 5%.[25] The low oral bioavailability is attributed to poor aqueous solubility and rapid first-pass metabolism, rendering oral administration therapeutically unviable.[2] The IV infusion allows for precise control of plasma concentrations, which is critical for maintaining a therapeutic effect and managing dose-related adverse events. Brexanolone exhibits dose-proportional pharmacokinetics over the clinically relevant infusion rate range of 30 to 270 mcg/kg/hour.[2]

Distribution

Following intravenous administration, Brexanolone is extensively distributed throughout the body. It is highly bound to plasma proteins, with a binding fraction greater than 99% that is independent of plasma concentration.[2] The volume of distribution (

Vd​) is approximately 3 L/kg, a value significantly larger than the volume of total body water, which indicates substantial distribution from the plasma into peripheral tissues.[2] This extensive distribution is consistent with its lipophilic steroid structure.

Metabolism

A key feature of Brexanolone's pharmacokinetic profile is its metabolism through pathways that are independent of the cytochrome P450 (CYP) enzyme system.[2] Metabolism occurs extensively via three main extra-hepatic routes:

1. Keto-reduction: Catalyzed by aldo-keto reductases.
2. Glucuronidation: Catalyzed by UDP-glucuronosyltransferases (UGTs).
3. Sulfation: Catalyzed by sulfotransferases (SULTs).

This metabolic profile is clinically significant for two reasons. First, it minimizes the potential for drug-drug interactions with the many medications that are substrates, inhibitors, or inducers of the CYP450 system. Second, it means that hepatic impairment does not significantly alter the drug's clearance, and therefore, no dosage adjustment is necessary for patients with liver disease.[2] The three predominant circulating metabolites produced through these pathways are all pharmacologically inactive and do not contribute to the drug's therapeutic effect.[4]

Elimination

Brexanolone has a terminal elimination half-life (t1/2​) of approximately 9 hours.[2] Total plasma clearance is approximately 1 L/hr/kg.[32] The drug is eliminated from the body following extensive metabolism. After administration of a radiolabeled dose, approximately 47% of the radioactivity was recovered in the feces and 42% in the urine, primarily as metabolites.[2] Less than 1% of the dose is excreted as unchanged Brexanolone in the urine, highlighting the completeness of its metabolic clearance.[32]

Special Populations

• Renal Impairment: While Brexanolone itself is not cleared renally to a significant extent, its formulation contains the solubilizing agent betadex sulfobutyl ether sodium, which is cleared by the kidneys. In patients with end-stage renal disease (ESRD) (eGFR <15 mL/min/1.73 m2), this agent can accumulate, posing a potential risk. Therefore, the use of Brexanolone is to be avoided in this population.[10] No dosage adjustment is required for patients with mild, moderate, or severe renal impairment (eGFR ≥15 mL/min/1.73 m2).[32]
• Lactation: Brexanolone is known to be transferred into breast milk. However, pharmacokinetic studies have shown that the relative infant dose (RID) is low, estimated to be between 1% and 2% of the maternal weight-adjusted dosage.[10] This low level of transfer, combined with the drug's poor oral bioavailability, suggests that infant exposure is minimal. Therefore, breastfeeding is not considered a contraindication, and it is not a reason to discontinue treatment if the mother requires it.[4]

Table 2: Summary of Brexanolone Pharmacokinetic Parameters

Parameter	Value	Clinical Implication	Source(s)
Administration Route	Continuous Intravenous Infusion	Required for therapeutic effect; allows precise dose control.	9
Oral Bioavailability	<5%	Oral administration is not feasible.	25
Elimination Half-Life (t1/2​)	~9 hours	Continuous infusion is necessary to maintain steady-state plasma concentrations.	2
Plasma Protein Binding	>99%	Extensive binding limits free drug concentration but is consistent across individuals.	2
Volume of Distribution (Vd​)	~3 L/kg	Indicates extensive distribution into body tissues.	2
Metabolism	Non-CYP450 pathways (keto-reduction, glucuronidation, sulfation)	Low potential for CYP-mediated drug interactions; no dose adjustment needed in hepatic impairment.	2
Excretion	Feces (~47%) and Urine (~42%) as inactive metabolites	Primary elimination is through metabolism, not direct renal excretion of active drug.	32

Clinical Efficacy in Postpartum Depression: The Hummingbird Program

The clinical efficacy of Brexanolone for the treatment of PPD was rigorously established through a comprehensive development program known as the Hummingbird program. This program included an open-label Phase 2 study and two pivotal, multicenter, randomized, double-blind, placebo-controlled Phase 3 trials (designated Study 202B and Study 202C) that provided the primary evidence for its FDA approval.[5]

Pivotal Trial Overview

The two Phase 3 trials were designed to evaluate the efficacy, safety, and tolerability of a 60-hour continuous intravenous infusion of Brexanolone compared to placebo in women with PPD.[5] The trials enrolled women who were six months postpartum or less and who met the DSM-IV criteria for a major depressive episode with onset in the third trimester or within four weeks of delivery.[34]

• Study 202B focused on patients with severe PPD, defined as a baseline Hamilton Rating Scale for Depression (HAM-D) total score of 26 or greater. Patients were randomized in a 1:1:1 ratio to receive Brexanolone at 90 µg/kg/h, Brexanolone at 60 µg/kg/h, or placebo.[5]
• Study 202C focused on patients with moderate PPD, defined as a baseline HAM-D score of 20 to 25. Patients were randomized in a 1:1 ratio to receive Brexanolone at 90 µg/kg/h or placebo.[5]

Primary Endpoint and Key Efficacy Results

The primary efficacy endpoint for both Phase 3 trials was the mean change from baseline in the 17-item HAM-D total score at the 60-hour time point, marking the end of the infusion.[5] The results from these studies consistently demonstrated a rapid, statistically significant, and clinically meaningful antidepressant effect.

• Rapid Onset of Action: A key finding across the clinical program was the remarkably rapid onset of therapeutic effect. An integrated analysis of the trials showed that a statistically significant improvement in HAM-D total score for Brexanolone compared to placebo was first observed as early as 24 hours after the initiation of the infusion.[18] This stands in stark contrast to traditional antidepressants, which often take weeks to work.
• Significant Symptom Reduction at 60 Hours: At the primary endpoint, all active treatment arms demonstrated superiority over placebo.
• In the severe PPD study (202B), the mean reduction in HAM-D score was 17.7 points for the 90 µg/kg/h group and 19.9 points for the 60 µg/kg/h group, compared to 14.0 points for placebo (p=0.0242 and p=0.0011, respectively).[5]
• In the moderate PPD study (202C), the mean reduction was 14.2 points for the 90 µg/kg/h group versus 12.0 points for placebo (p=0.0160).[5]
• An integrated analysis of the 90 µg/kg/h dose across studies found an average reduction of 17.0 points for Brexanolone versus 12.8 points for placebo (p<0.0001).[18]
• Sustained Effect and Remission: The antidepressant effect was shown to be durable. The significant reduction in depressive symptoms observed at 60 hours was maintained through the 30-day follow-up period in both Phase 3 trials.[2] Furthermore, Brexanolone treatment led to high rates of remission (defined in the trials as a HAM-D score ≤7). In an earlier Phase 2 study of women with severe PPD, 70% of those treated with Brexanolone achieved remission at 60 hours, compared to only 9% (one patient) in the placebo group.[3] Across the integrated dataset, 94% of responders at Day 30 had not relapsed.[39]

The collective evidence from the Hummingbird program demonstrated that Brexanolone offered a novel, rapid, and durable treatment effect for both moderate and severe PPD, directly addressing the critical unmet need for a fast-acting therapy in this vulnerable population. The quantitative results are summarized in Table 3.

Table 3: Key Efficacy Outcomes from Pivotal Phase 3 Trials (Hummingbird Program)

Study ID	PPD Severity	Treatment Arm (Dose)	N	Baseline HAM-D (Mean)	Change in HAM-D at 60h (Mean)	P-value vs. Placebo	Source(s)
Study 202B	Severe	Brexanolone 90 µg/kg/h	~41	≥26	-17.7	0.0242	5
	(HAM-D ≥26)	Brexanolone 60 µg/kg/h	~41	≥26	-19.9	0.0011	5
		Placebo	~40	≥26	-14.0	-	5
Study 202C	Moderate	Brexanolone 90 µg/kg/h	~52	20-25	-14.2	0.0160	5
	(HAM-D 20-25)	Placebo	~52	20-25	-12.0	-	5

Safety, Tolerability, and Risk Management

While Brexanolone demonstrated significant efficacy, its safety profile presented major challenges that ultimately defined its clinical use and market trajectory. The primary concern revolved around its potent CNS depressant effects, which necessitated stringent risk management protocols.

Boxed Warning: Excessive Sedation and Sudden Loss of Consciousness

The most significant safety risk associated with Brexanolone is the potential for excessive sedation and sudden loss of consciousness. This risk is highlighted in a Boxed Warning on the drug's prescribing information, the FDA's most stringent warning for prescription drugs.[7] In clinical trials, some patients experienced a sudden loss or altered state of consciousness during the infusion, occurring in approximately 4% of Brexanolone-treated patients compared to 0% in the placebo group.[6] These events could occur without preceding signs of sedation and were unpredictable in their timing or relation to dose levels.[40] Recovery was typically rapid (15-60 minutes) upon stopping the infusion, but the potential for serious harm, particularly if a patient were unattended, was deemed substantial.[34]

Common Adverse Events

In pivotal clinical trials, Brexanolone was generally well-tolerated by most patients, but a distinct profile of adverse events emerged. The most common adverse reactions, occurring at an incidence of 5% or more and at least twice the rate of placebo, were [2]:

• Sedation/Somnolence (15-21%)
• Dry Mouth (3-11%)
• Loss of Consciousness (~4%)
• Flushing/Hot Flush (~5%)

Other frequently reported events included dizziness, presyncope, and vertigo (12-13%).[6] Post-marketing surveillance data collected between 2019 and 2021 suggested that the real-world rates of excessive sedation (<1%) and loss of consciousness (0%) were lower than those observed in the controlled environment of clinical trials, though the risk remained a central concern.[6]

Drug Interactions

The CNS depressant effects of Brexanolone are additive with other substances that suppress the central nervous system. The prescribing information specifically warns that concomitant use with other CNS depressants—such as opioids, benzodiazepines, alcohol, or even other antidepressants—may increase the likelihood and severity of sedation-related adverse reactions.[8] In clinical studies, a higher percentage of Brexanolone-treated patients who were also taking other antidepressants reported sedation-related events.[27]

ZULRESSO Risk Evaluation and Mitigation Strategy (REMS) Program

Due to the serious risk of harm from excessive sedation and sudden loss of consciousness, the FDA mandated that Brexanolone be available only through a restricted program known as the ZULRESSO REMS.[6] This program imposed strict controls on the prescribing and administration of the drug. Key requirements included [6]:

1. Certified Facilities: The drug could only be administered in a healthcare facility (e.g., hospital or infusion center) that was certified in the REMS program.
2. Patient Enrollment: Each patient had to be enrolled in the REMS program before treatment could begin.
3. Continuous Monitoring: A healthcare provider had to be available on-site to continuously monitor the patient for the entire duration of the 60-hour infusion. This included continuous pulse oximetry to detect hypoxia and assessments for excessive sedation every two hours during non-sleep periods.
4. Accompaniment: Patients were required to be accompanied during any interactions with their children to prevent potential harm in the event of a sudden loss of consciousness.

While these measures were essential for ensuring patient safety, they also created the primary obstacles to the drug's widespread adoption. The requirement for a 60-hour inpatient admission to a certified facility was a profound logistical and emotional burden for a new mother, necessitating separation from her newborn.[39] Furthermore, it dramatically increased the overall cost of treatment, adding facility and monitoring expenses to the drug's already high price tag of approximately $34,000 per treatment course.[11] Many psychiatric facilities were not equipped to handle complex IV infusions, creating a bottleneck for access.[39] Ultimately, the safety profile of Brexanolone dictated a delivery model that, while safe, was clinically impractical, economically prohibitive, and unsustainable for broad clinical use, crippling its market potential from the outset.

Prescribing Information and Clinical Administration

The clinical administration of Brexanolone is a highly structured and monitored process, governed by its specific indication, complex dosing schedule, and the requirements of the REMS program.

Indication

Brexanolone (Zulresso) is indicated for the treatment of postpartum depression (PPD).[1] The approval initially covered adult women, and in June 2022, the indication was expanded to include adolescent patients aged 15 years and older.[6] It is the only indication for which the drug was approved.

Administration Protocol and Dosage Titration

Brexanolone must be administered as a continuous, weight-based intravenous infusion over a total of 60 hours (2.5 days) using a programmable peristaltic infusion pump via a dedicated IV line.[8] The infusion follows a specific step-wise titration schedule designed to gradually increase the dose to a maintenance level and then taper it down before discontinuation. This schedule is detailed in Table 4.

Table 4: Brexanolone (Zulresso) 60-Hour Intravenous Infusion Schedule

Time Interval (Hours)	Infusion Rate (mcg/kg/hour)	Key Actions and Considerations	Source(s)
0 – 4	30	Initiate infusion. Begin continuous pulse oximetry and sedation monitoring.	8
4 – 24	60	Increase infusion rate as scheduled.	8
24 – 52	90	Increase to maximum recommended infusion rate. Consider reducing to 60 mcg/kg/h if the 90 mcg/kg/h rate is not tolerated.	8
52 – 56	60	Begin dose taper by decreasing infusion rate.	8
56 – 60	30	Continue dose taper to final rate before discontinuation.	8

Preparation and Dilution

Zulresso is supplied as a concentrated solution in single-dose vials (100 mg/20 mL, or 5 mg/mL) that must be diluted prior to administration using proper aseptic technique.[8] The preparation for a standard 60-hour infusion typically requires five or more infusion bags. For each bag, 20 mL of the drug concentrate is transferred to a polyolefin infusion bag and diluted first with 40 mL of Sterile Water for Injection and then with 40 mL of 0.9% Sodium Chloride Injection. This results in a final infusion solution with a total volume of 100 mL and a Brexanolone concentration of 1 mg/mL.[8] Diluted solutions must be refrigerated if not used immediately and can be stored for up to 96 hours.[10]

Monitoring Requirements

Due to the risks outlined in the Boxed Warning, patient monitoring is the cornerstone of safe Brexanolone administration. The following monitoring protocols are mandatory under the REMS program:

• A healthcare provider must be available on-site for the entire duration of the infusion.[16]
• The patient must be monitored for hypoxia using continuous pulse oximetry equipped with an alarm.[10] If hypoxia is detected, the infusion must be stopped immediately and not resumed.[33]
• The patient must be assessed for excessive sedation at least every two hours during planned, non-sleep periods.[16] If excessive sedation occurs, the infusion should be stopped until symptoms resolve. The infusion may then be resumed at the same or a lower dose as deemed clinically appropriate.[33]

Comparative Landscape and Economic Analysis

The clinical and commercial context of Brexanolone is best understood by comparing it to the established standard of care for PPD, selective serotonin reuptake inhibitors (SSRIs), and by considering its relationship with its oral successor, Zuranolone.

Brexanolone vs. SSRIs

Brexanolone and SSRIs represent two vastly different therapeutic approaches to PPD, each with a distinct profile of advantages and disadvantages.

• Efficacy and Onset of Action: This is Brexanolone's most significant advantage. Clinical trials demonstrated a rapid onset of antidepressant effects, with significant symptom reduction within 24-60 hours.[3] In contrast, SSRIs have a well-documented therapeutic lag, typically requiring two to six weeks to achieve their maximal effect.[9] For a mother in the acute distress of severe PPD, this difference in onset is profound.
• Administration and Access: This is Brexanolone's greatest liability. It requires a complex, 60-hour continuous IV infusion within a certified inpatient facility, creating major logistical, financial, and emotional hurdles.[9] SSRIs, conversely, are administered as a simple once-daily oral pill that can be taken at home, offering unparalleled convenience and accessibility.[45]
• Cost: The financial disparity is staggering. A single course of Brexanolone treatment was priced at approximately $34,000 for the drug alone, with total costs rising significantly when facility and monitoring fees were included.[11] Generic SSRIs, such as sertraline, are available for a few dollars per monthly supply.[45]
• Safety and Tolerability: While SSRIs have their own side effect profile (e.g., gastrointestinal upset, sexual dysfunction), Brexanolone's primary risks of sudden loss of consciousness and excessive sedation are more acute and severe, necessitating the restrictive REMS program.[7]

Table 5: Comparative Profile: Brexanolone vs. Traditional SSRIs for PPD

Feature	Brexanolone (Zulresso)	SSRIs (e.g., Sertraline)	Source(s)
Mechanism of Action	Positive Allosteric Modulator of GABAA​ Receptors	Selective Serotonin Reuptake Inhibitor	4
Onset of Action	Rapid (24-60 hours)	Delayed (2-6 weeks)	3
Route of Administration	60-hour continuous IV infusion in a certified facility	Once-daily oral tablet at home	9
Duration of Treatment	Single 60-hour course	Minimum 6 months	10
Approximate Drug Cost	~$34,000 per course	<$30 per month (generic)	11
Key Safety Concerns	Excessive sedation, sudden loss of consciousness (Boxed Warning), requires REMS	Nausea, headache, sexual dysfunction, potential for increased suicidal thoughts in young adults	6

Cost-Effectiveness Analysis

Despite its high upfront cost, economic modeling has suggested that Brexanolone could be considered cost-effective under certain assumptions. A study projecting costs and quality-adjusted life-years (QALYs) over an 11-year time horizon for mothers and their children estimated the incremental cost-effectiveness ratio (ICER) for Brexanolone versus SSRIs to be $106,662 per QALY gained.[17] While the drug and administration costs for Brexanolone were vastly higher ($38,501 vs. $25 for SSRIs), the model projected lower total direct medical costs for the mother over the long term in the Brexanolone arm ($65,908 vs. $73,653), likely due to faster and more effective resolution of the initial depressive episode.[17] At a willingness-to-pay threshold of $150,000 per QALY, Brexanolone was found to be cost-effective with a 58% probability.[17] The results were highly sensitive to the model's time horizon and the baseline severity of PPD, with the ICER becoming much more favorable in severe PPD and over longer time horizons.[17]

The Role of Zuranolone

The development of Zuranolone (Zurzuvae) by Sage Therapeutics was a direct response to the practical limitations of Brexanolone. Zuranolone is a next-generation oral neurosteroid analogue that shares Brexanolone's mechanism as a positive allosteric modulator of GABAA​ receptors but is formulated for once-daily oral administration over a 14-day course.[46] It offers the potential for rapid antidepressant effects similar to Brexanolone but without the need for a prolonged inpatient IV infusion.[45] The approval and launch of Zuranolone for PPD created an internal competitor that was far more convenient, scalable, and commercially viable, which was a primary factor in the strategic decision to discontinue Brexanolone.[13]

Regulatory Journey and Market Discontinuation

Path to Approval

Brexanolone's path to market was marked by an accelerated regulatory process, reflecting its status as a potential breakthrough for a serious condition with limited treatment options. The key milestones in its regulatory journey were [19]:

• April 23, 2018: Sage Therapeutics submitted a New Drug Application (NDA) to the U.S. FDA.
• May 30, 2018: The FDA accepted the NDA for filing and granted it Priority Review status, a designation that shortens the review timeline.
• November 2, 2018: The FDA's Psychopharmacologic Drugs Advisory Committee voted overwhelmingly (17-1) in favor of approval, concluding that the benefits of Brexanolone outweighed its risks for the treatment of PPD.
• March 19, 2019: The FDA officially approved Zulresso (Brexanolone) injection, making it the first-ever drug specifically indicated for PPD.

Commercial Challenges

Despite its landmark approval and strong clinical data, Brexanolone faced immediate and severe commercial headwinds. The combination of its high price tag (approximately $34,000 per treatment), the additional costs of a multi-day hospital stay, and the logistical complexity of the REMS program created a formidable barrier to access.[11] Payers were hesitant to establish reimbursement pathways for such a costly and complex treatment, and healthcare systems struggled to implement the required infrastructure for certified infusion sites.[39] For patients, the prospect of a 2.5-day separation from their newborn was a significant deterrent.[43] As a result, market uptake was extremely limited, and the drug failed to generate significant revenue. Sales figures reflected this struggle, with revenue declining 63% to just $3.1 million in the first nine months of one of its final years on the market.[13]

Strategic Discontinuation and Formal Withdrawal

The commercial fate of Brexanolone was ultimately sealed by its own developer's innovation. Sage Therapeutics was concurrently developing Zuranolone, an oral successor designed to overcome the very administration challenges that plagued Brexanolone. The availability of a more convenient oral agent with a similar rapid-acting mechanism rendered the cumbersome and expensive IV formulation strategically redundant.

This dynamic illustrates a unique "pipeline-in-a-product" scenario. Brexanolone served as an essential proof-of-concept, validating the therapeutic target and demonstrating the clinical potential of neurosteroid modulation for PPD. However, its own delivery system was its fatal flaw. The market, aware that a more practical oral version was in late-stage development, had little incentive to invest in the complex infrastructure needed for the first-generation IV drug. Once Zuranolone gained FDA approval for PPD, the business case for continuing to market Zulresso dissolved entirely.

In late 2024, Sage Therapeutics announced it would discontinue Zulresso to focus its resources on the commercialization of Zuranolone.[13] The company formally notified the FDA that the product was no longer being marketed and requested the withdrawal of its NDA (NDA 211371). The FDA granted the request, with the official withdrawal of approval to become effective on April 14, 2025.[12]

Future Perspectives and Scientific Legacy

Although its time on the market was brief, the scientific and clinical legacy of Brexanolone is substantial and will continue to influence the field of psychiatry for years to come.

Validating a New Mechanism

Brexanolone's most enduring contribution is the clinical validation of the neurosteroid pathway and GABAA​ receptor modulation as a viable and effective strategy for treating a major mood disorder.[15] For decades, antidepressant development was largely focused on monoaminergic systems (serotonin, norepinephrine, dopamine). Brexanolone's success demonstrated that targeting the brain's primary inhibitory system could produce rapid and profound antidepressant effects, opening an entirely new frontier for research and drug development in depression and other stress-related disorders.[49] It provided the first clinical proof that PPD may, at least in part, be a disorder of neurosteroid deficiency, shifting the conceptual framework of the illness.

Paving the Way for Oral Formulations

The significant practical challenges associated with Brexanolone's 60-hour IV infusion highlighted the critical importance of formulation and delivery methods in clinical adoption. These challenges directly motivated and created a clear market imperative for the development of oral neurosteroids like Zuranolone.[43] Brexanolone's journey demonstrated that a novel mechanism, however effective, is insufficient for commercial success if the administration is not practical for the target patient population. It thus served as a crucial, albeit costly, stepping stone to a more accessible generation of therapies.

Potential for Other Indications

The mechanism of action of Brexanolone suggests potential utility beyond PPD. Neurosteroid dysregulation and GABAergic dysfunction have been implicated in a range of CNS disorders. Consequently, Brexanolone and related compounds have been or are being explored for other indications. Early research investigated its use in refractory seizure disorders, and ongoing clinical trials are evaluating its potential in conditions such as Post-Traumatic Stress Disorder (PTSD) and essential tremor.[31] While Brexanolone itself may not be pursued for these uses due to its formulation, the scientific rationale it established continues to drive research in these areas.

Future Research Directions

The advent of Brexanolone has illuminated several key areas for future research. A primary need is for more data on the long-term efficacy and safety of neurosteroid-based treatments beyond the 30-day follow-up period of the pivotal trials.[2] Understanding the durability of the response and whether repeat treatment courses are necessary is critical. The FDA, at the time of approval, recommended further studies to determine if the infusion protocol could be shortened or administered intermittently (e.g., only during daytime hours) to improve practicality.[41]

Moreover, the field now requires head-to-head comparative effectiveness trials, not only between novel neurosteroids and traditional SSRIs but also between different neurosteroids (e.g., Brexanolone vs. Zuranolone) to establish a clearer therapeutic hierarchy and guide clinical decision-making.[21] Finally, further basic and translational research is needed to refine our understanding of the precise molecular mechanisms of neurosteroid action and to identify biomarkers that could predict which patients are most likely to respond to this class of medication, paving the way for a more personalized approach to treating PPD and other mood disorders.[49]

Works cited

1. Allopregnanolone | C21H34O2 | CID 92786 - PubChem, accessed September 2, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Allopregnanolone
2. Brexanolone - StatPearls - NCBI Bookshelf, accessed September 2, 2025, https://www.ncbi.nlm.nih.gov/books/NBK541054/
3. Brexanolone: an allosteric modulator of GABA-A receptors in the ..., accessed September 2, 2025, https://www.tandfonline.com/doi/full/10.1080/24750573.2017.1380352
4. Brexanolone: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed September 2, 2025, https://go.drugbank.com/drugs/DB11859
5. Sage Therapeutics Announces Brexanolone Achieves Primary ..., accessed September 2, 2025, https://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-announces-brexanolone-achieves-primary
6. Safety of Brexanolone in Adults with Postpartum Depression: Postmarketing Surveillance Data - PMC, accessed September 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10491550/
7. Brexanolone for Postpartum Depression, accessed September 2, 2025, https://medicalpolicy.bcbstx.com/content/dam/bcbs/medicalpolicy/pdf/rx/RX501.106_2024-12-15.pdf
8. Zulresso - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed September 2, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211371lbl.pdf
9. Brexanolone Is the First Drug Specifically for Postpartum Depression - AWHONN, accessed September 2, 2025, https://www.awhonn.org/wp-content/uploads/2020/04/Brexanolone-is-the-First-Drug-Specifically-for-PPD_NWH-2019.pdf
10. Brexanolone Monograph for Professionals - Drugs.com, accessed September 2, 2025, https://www.drugs.com/monograph/brexanolone.html
11. Treating Postpartum Depression: What Do We Know about Brexanolone? - MDPI, accessed September 2, 2025, https://www.mdpi.com/2079-9721/9/3/52
12. Sage Therapeutics, Inc.; Withdrawal of Approval of a New Drug Application for ZULRESSO (Brexanolone) Solution, 100 Milligrams/20 Milliliters - Federal Register, accessed September 2, 2025, https://www.federalregister.gov/documents/2025/03/14/2025-04101/sage-therapeutics-inc-withdrawal-of-approval-of-a-new-drug-application-for-zulresso-brexanolone
13. Biogen and Sage Therapeutics Halt Development of Depression Drug - Patsnap Synapse, accessed September 2, 2025, https://synapse.patsnap.com/article/biogen-and-sage-therapeutics-halt-development-of-depression-drug
14. Biogen, Sage admit a defeat in major depression | BioPharma Dive, accessed September 2, 2025, https://www.biopharmadive.com/news/biogen-sage-zurzuvae-discontinue-major-depressive-disorder/731459/
15. Basic Research Powers the First Medication for Postpartum Depression, accessed September 2, 2025, https://www.nimh.nih.gov/news/science-updates/2024/basic-research-powers-the-first-medication-for-postpartum-depression
16. Zulresso (brexanolone) - Iowa Department of Health and Human Services, accessed September 2, 2025, https://hhs.iowa.gov/media/428/download?inline
17. Cost-Effectiveness of Brexanolone Versus Selective Serotonin ..., accessed September 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10391201/
18. Analysis finds investigational medication reduced postpartum depression symptoms in clinical trial | Northwell Health, accessed September 2, 2025, https://feinstein.northwell.edu/news/the-latest/analysis-finds-investigational-medication-reduced-postpartum-depression-symptoms-in-clinical-trial
19. Zulresso (brexanolone) FDA Approval History - Drugs.com, accessed September 2, 2025, https://www.drugs.com/history/zulresso.html
20. Brexanolone for the treatment of patients with postpartum depression - PubMed, accessed September 2, 2025, https://pubmed.ncbi.nlm.nih.gov/31584571/
21. Brexanolone Injection for Postpartum Depression | Health.mil, accessed September 2, 2025, https://www.health.mil/Reference-Center/Publications/2023/12/19/Brexanolone-Injection-for-Postpartum-Depression
22. Preclinical and clinical pharmacology of brexanolone (allopregnanolone) for postpartum depression: a landmark journey from concept to clinic in neurosteroid replacement therapy - PMC - PubMed Central, accessed September 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10471722/
23. Allopregnanolone | 516-54-1 - ChemicalBook, accessed September 2, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5418550.htm
24. Allopregnanolone (exempt preparation) (CAS 516-54-1) - Cayman Chemical, accessed September 2, 2025, https://www.caymanchem.com/product/43516/allopregnanolone-(exempt-preparation)
25. en.wikipedia.org, accessed September 2, 2025, https://en.wikipedia.org/wiki/Allopregnanolone
26. Brexanolone - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed September 2, 2025, https://www.ncbi.nlm.nih.gov/books/NBK540687/
27. Brexanolone: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed September 2, 2025, https://www.rxlist.com/brexanolone/generic-drug.htm
28. brexanolone - Drug Central, accessed September 2, 2025, https://drugcentral.org/drugcard/5324
29. www.ncbi.nlm.nih.gov, accessed September 2, 2025, https://www.ncbi.nlm.nih.gov/books/NBK541054/#:~:text=Brexanolone%20is%20a%20medication%20used,A%20modulator%20class%20of%20medications.
30. Brexanolone, a GABAA Modulator, in the Treatment of Postpartum Depression in Adults: A Comprehensive Review - Frontiers, accessed September 2, 2025, https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2021.699740/pdf
31. Understanding the Clinical Effects and Mechanisms of Action of Neurosteroids, accessed September 2, 2025, https://psychiatryonline.org/doi/10.1176/appi.ajp.2020.20020134
32. FDA Approves ZULRESSO (Brexanolone) for Postpartum Depression in Adults, accessed September 2, 2025, https://accp1.org/Members/ACCP1/5Publications_and_News/FDA-Approves-ZULRESSO-Postpartum-Depression-Adults.aspx
33. Zulresso (brexanolone) dosing, indications, interactions, adverse effects, and more, accessed September 2, 2025, https://reference.medscape.com/drug/zulresso-brexanolone-1000299
34. Brexanolone (Zulresso) - Medical Clinical Policy Bulletins - Aetna, accessed September 2, 2025, https://www.aetna.com/cpb/medical/data/900_999/0951.html
35. Brexanolone: A New Drug for Postpartum Depression, accessed September 2, 2025, https://womensmentalhealth.org/posts/brexanolone_new_drug_postpartum_depression/
36. Sage Therapeutics Announces The Lancet Publishes Integrated Data from Pivotal Trials for Brexanolone Injection in Postpartum Depression, accessed September 2, 2025, https://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-announces-lancet-publishes-integrated-data
37. 01. Effect of Brexanolone on Postpartum Depressive Symptoms, Anxiety, and Insomnia, accessed September 2, 2025, https://psychopharmacologyinstitute.com/section/effect-of-brexanolone-on-postpartum-depressive-symptoms-anxiety-and-insomnia-2737-5503/
38. Brexanolone Reduces Postpartum Depression in Preliminary Clinical Trial, accessed September 2, 2025, https://bbrfoundation.org/content/brexanolone-reduces-postpartum-depression-preliminary-clinical-trial
39. Brexanolone (Zulresso®) FDA approved March 2019, Sage Therapeutics Inc. (Controlled substance Schedule IV) Indication: Brexanol, accessed September 2, 2025, https://www.smchealth.org/sites/main/files/file-attachments/zulresso_brexanolone_publish.pdf?1589827052
40. PRESCRIBING INFORMATION - ZULRESSO® (brexanolone) injection, for intravenous use, CIV - Sage Therapeutics, accessed September 2, 2025, https://assets.sagerx.com/zulresso/prescribing-information.pdf
41. Multi-Discipline Review - accessdata.fda.gov, accessed September 2, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211371Orig1s000MultidisciplineR.pdf
42. Post-Marketing Safety Data for Brexanolone (Zulresso), accessed September 2, 2025, https://womensmentalhealth.org/posts/post-marketing-safety-data-for-brexanolone-zulresso/
43. Brexanolone Passes Phase 3 Hurdle | Psychiatric News - Psychiatry Online, accessed September 2, 2025, https://psychiatryonline.org/doi/10.1176/appi.pn.2018.pp10a2
44. Risk Assessment and Risk Mitgation Review(s) - accessdata.fda.gov, accessed September 2, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211371Orig1s000RiskR.pdf
45. Your Patient Has Postpartum Depression: Do You Use Zuranolone or a Traditional Antidepressant?, accessed September 2, 2025, https://womensmentalhealth.org/posts/zuranolone-or-traditional-antidepressant-for-postpartum-depression/
46. More Data on the Neuroactive Steroid Zuranolone for Postpartum Depression, accessed September 2, 2025, https://womensmentalhealth.org/posts/zuranolone-postpartum-depression/
47. The Role of Brexanolone and Zuranolone in Postpartum Depression, accessed September 2, 2025, https://psychopharmacologyinstitute.com/section/the-role-of-brexanolone-and-zuranolone-in-postpartum-depression-2826-5785
48. Biogen, Sage Therapeutics Drop Plans to Develop Partnered Drug in Major Depressive Disorder - MedCity News, accessed September 2, 2025, https://medcitynews.com/2024/10/biogen-sage-therapeutics-zurzuvae-major-depressive-disorder-depression-biib/
49. From Brexanolone to Psychedelics: The New Frontier in Pharmacologic Psychiatry - McGovern Medical School - UTHealth Houston, accessed September 2, 2025, https://med.uth.edu/psychiatry/2025/07/07/from-brexanolone-to-psychedelics-the-new-frontier-in-pharmacologic-psychiatry/
50. Brexanolone Recruiting Phase 2 Trials for Post Traumatic Stress Disorder (PTSD) Basic Science | DrugBank Online, accessed September 2, 2025, https://go.drugbank.com/drugs/DB11859/clinical_trials?conditions=DBCOND0038601&phase=2&purpose=basic_science&status=recruiting